Several phase 2 trials indicated that MDMA-AT has an acceptable risk–benefit profile in individuals with PTSD13. A pivotal phase 3 study (MAPP1) showed that MDMA-AT was generally well tolerated and met the trial’s primary and secondary endpoints of reduced PTSD symptom severity and decreased functional impairment12. The secondary objective of this trial was to evaluate […]
Archive for the ‘Sober living’ Category
Australia to allow MDMA-assisted therapy for PTSD Alcohol and Drug Foundation
December 6th, 2022 
Ralph 
Posted in 